Stapokibart (CM310) is a humanized monoclonal antibody targeting IL-4Rα, blocking IL-4Rα-mediated signaling. It is used in studies of atopic dermatitis.

Stapokibart showed high affinity binding to IL-4Rα in human, cynomophage monkey and rat with equilibrium dissociation constant (KD) values of 0.25, 1.5 and 2.75 nM and IC50 values of 0.40 nM, respectively.
In HEK293-STAT6 reporter cells, Stapokibart showed concentration-dependent inhibition of IL-4 - or IL-13-induced STAT6 activation, with IC50 values of 0.039 nM and 0.041 nM, respectively.
In TF-1 cells, Stapokibart effectively inhibited IL-4 and IL-13-induced cell proliferation, with IC50 values of 1.75 nM and 0.13 nM, respectively. [1]

In an OVA-induced asthma model, Stapokibart showed protective effects against IL-4/IL-13 induced airway inflammation in rats.
Stapokibart (25, 50, 100 mg/kg) reduces disease severity of OVA-induced rhinitis in rats. [1]

Human

Monoclonal

Unconjugated